case_images: PMC4302222_01
case_images: Multiple organ failure is temporally associated with new prescriptions of paroxetine, and was classified as meriting further evaluation on account of the temporal asymmetry and the importance of the medical event. IC information component
case_images: 40264_2014_251_Fig2_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig2_HTML.jpg
case_images: Fig2
case_images: The chronograph is based on very limited data, but there are no patients with multiple organ failure events in the 3 years leading up to initiation of treatment with paroxetine (see Fig. 2).
case_images: Skin sensation disturbance is temporally associated with new prescriptions of salmeterol, and was classified as meriting further evaluation on account of the lack of a clear alternative explanation for the suggestive temporal pattern. IC information component
case_images: 40264_2014_251_Fig3_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig3_HTML.jpg
case_images: Fig3
case_images: In the chronograph, there is a transient increase in the event rate from month 2, with a decrease in the event rate in the month immediately before and after treatment initiation (see Fig. 3).
case_images: Epiphora is temporally associated with new prescriptions of amiloride, and was classified as meriting further evaluation on account of the suggestive temporal pattern and a possibly supporting animal study. IC information component
case_images: 40264_2014_251_Fig4_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig4_HTML.jpg
case_images: Fig4
case_images: In the chronograph, there is a transient increase in the event rate most pronounced from month 4 to 7, with no prior elevation (see Fig. 4).
case_images: Other Eustachian tube disorder is temporally associated with new prescriptions of gentamicin, but was dismissed from further evaluation on the basis of the observed temporal pattern, with an increased rate in the months leading up to prescription. IC information component
case_images: 40264_2014_251_Fig5_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig5_HTML.jpg
case_images: Fig5
case_images: While the observed-to-expected ratio for the surveillance period is higher than those in each control period, the rate already begins to increase in the months leading up to the new gentamicin prescription (see Fig. 5), which supports the suspicion that gentamicin may have been prescribed for the Eustachian tube disorder or earlier manifestations thereof.
case_images: Endometriosis is temporally associated with new prescriptions of hyoscine, but was dismissed from further evaluation on account of suspected protopathic bias. IC information component
case_images: 40264_2014_251_Fig6_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig6_HTML.jpg
case_images: Fig6
case_images: IC 025 = 0.99). In the chronograph, there is a gradual increase in the observed-to-expected ratio with a peak between month 3 and 7 (see Fig. 6).
case_images: Open-angle glaucoma is temporally associated with new prescriptions of dithranol, but was dismissed from further evaluation since three of four patients had similar events recorded prior to initiation of dithranol treatment. IC information component
case_images: 40264_2014_251_Fig7_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig7_HTML.jpg
case_images: Fig7
case_images: The chronograph is based on limited data, but there is only one patient with open-angle glaucoma in the 3 years before new dithranol prescriptions (see Fig. 7).
case_images: Proportion of relevant drug-event pairs classified as 'Labeled.' Each pie chart represents one of the six assessors
case_images: 40264_2014_251_Fig8_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig8_HTML.jpg
case_images: Fig8
case_images: Figures 8 and 9 show the proportion of drug-event pairs classified as 'Labeled' and 'Merits further evaluation' by each assessor.
case_images: Proportion of relevant and unlabeled drug-event pairs classified as 'Merits further evaluation.' Each pie chart represents one of the six assessors
case_images: 40264_2014_251_Fig9_HTML.jpg
case_images: PMC4302222_01_40264_2014_251_Fig9_HTML.jpg
case_images: Fig9
case_images: Figures 8 and 9 show the proportion of drug-event pairs classified as 'Labeled' and 'Merits further evaluation' by each assessor. Whereas the proportions of drug-event pairs classified as labeled are similar, there is substantial variability between assessors with respect to the proportion of combinations that were classified as meriting further evaluation; these proportions range from 5 to 47 % (Fig. 9).